BioMarin Pharmaceuticals (BMRN) Comprehensive Income (Loss), Net of Tax, Attributable to Parent — Quarterly & Annual

Screener

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Sarepta Therapeutics, Inc.SRPT

-$5.33M-103%

RegenxbioRGNX

$22.7M+132%

Tyra Biosciences, Inc.TYRA

-$39.59M-40.2%

Crinetics PharmaceuticalsCRNX

-$130.96M-36.8%

MBX Biosciences, Inc.MBX

-$24.41M-2.2%

XER

Xeris Biopharma Holdings, Inc.XERS

-$31.09M-1,513%

Other financials

Income statement

Revenue$989.7M+19.9%

Gross profit$786.9M+16.5%

Operating income$110.9M-59.9%

Net income$44.8M-81.4%

EPS (diluted)$0.23-81.3%

Balance sheet

Cash & equivalents$874.0M-28.0%

Total debt$4.2B+598%

Total equity$6.3B+4.9%

Total assets$11.7B+57.2%

Cash flow

Operating cash flow$168.1M-9.3%

CapEx$28.8M+68.5%

Free cash flow$139.3M-17.2%

Valuation

Market cap$12.35B+12.2%

Enterprise value$15.66B+50.7%

P/E34.3×-37.0×

P/S3.6×0.0×

Profitability

Gross margin76.1%-3.4pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin21.7%-1.0pp

Returns & leverage

Return on equity9.1%+2.8pp

Debt / equity0.7×+0.6×

Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:14 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001048477-26-000016

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
INCOME BEFORE INCOME TAXES	61,384	297,868	202,587	535,957
Provision for income taxes	16,622	57,336	52,298	109,739
NET INCOME	$44,762	$240,532	$150,289	$426,218
EARNINGS PER SHARE, BASIC	$0.23	$1.25	$0.78	$2.23
EARNINGS PER SHARE, DILUTED	$0.23	$1.23	$0.77	$2.19
Weighted average common shares outstanding, basic	193,423	191,907	192,959	191,440
Weighted average common shares outstanding, diluted	194,467	197,091	194,147	196,643
COMPREHENSIVE INCOME	$40,216	$176,816	$154,979	$320,000

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?: BioMarin Pharmaceuticals (BMRN) reported comprehensive income (loss), net of tax, attributable to parent of $40.22M in Q2 2026.
How has BioMarin Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?: BioMarin Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 77.3% year-over-year, from $176.82M to $40.22M.
What does comprehensive income (loss), net of tax, attributable to parent mean?: Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Ask your AI about BioMarin Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk